Signifor
- Prescription status not stated
- Hormones, such as thyroid and steroids
- Active substance
- Pasireotide
- Made by
- Recordati Rare Diseases
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Signifor is indicated for the treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed. Signifor is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.
From the official label · 2026-09-30 · European Medicines Agency
How it works
From the US prescribing label for the same active substance (Signifor). It describes the substance, not this exact product.
SIGNIFOR is an injectable cyclohexapeptide somatostatin analogue.
Pasireotide exerts its pharmacological activity via binding to somatostatin receptors (SSTRs).
Metabolism and Excretion Pasireotide was shown to be metabolically stable in human liver and kidney microsomes systems.
Pasireotide is eliminated mainly via hepatic clearance (biliary excretion) with a small contribution of the renal route.
Food effect is unlikely to occur since SIGNIFOR is administered via a parenteral route.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-02-17
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Recordati Rare Diseases |
|---|---|
| Active substance | Pasireotide |
| Used in | Hormones, such as thyroid and steroids |
| Classification | H01CB05 · Hormones, such as thyroid and steroids |
| Authorised on | 2012-04-24 |
| Last updated by the regulator | 2026-08-05 |
| EMA product number | EMEA/H/C/002052 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).